Document text
Recommendations from the Combined Immunization
Schedule Work Group for the 2025 Immunization
Schedules for Children/Adolescents and Adults
Sybil Cineas, MD, FAAP , FACP (ACIP Combined Immunization WG Chair)
Nanda Issa, MD (CDC Co -Lead )
Patricia Wodi, MD (CDC acting Co -Lead)
ACIP Meeting
October 24, 2024National Center for Immunization and Respiratory Diseases
Dr. Nanda Issa2025 Update to Child and Adolescent Immunization Schedule
Age 18 years or younger
How to Use the Immunization Schedule
Sections
•Cover Page
•Table 1: Age -based
•Table 2: Catch -up
•Table 3: Medical indication
•Vaccination notes
•Appendix: contraindications
and precautions
•Addendum: updates after
schedule is published
Child and Adolescent Immunization Schedule by Age (Addendum updated June 27, 2024) | Vaccines & Immunizations | CDC
3
Proposed Update to the 2025 Child/Adolescent Immunization
Schedule
Changes to Tables
•Cover Page
•Table 1
•Table 2
•Table 3Changes to Vaccination Notes
•COVID -19
•DTaP
•Hib
•Influenza
•MMR
•MenB
•Pneumococcal
•RSV monoclonal antibody
•RSV vaccineChanges to Appendix
•MMR/MMRV
•Varicella
1. Use of COVID -19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — Unite d States, 2024 –2025 | MMWR (cdc.gov)
2. Use of Haemophilus influenzae Type b –Containing Vaccines Among American Indian and Alaska Native Infants: Updated Recommendation s of the Advisory Committee on Immunization Practices ― United
States, 2024 | MMWR (cdc.gov)
3. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practic es — United States, 2024 –25 Influenza Season | MMWR (cdc.gov) 4
Cover page
6
Table 1
Immunization schedule by age group
8
9
10
11
12
Table 2
Catch -up immunization schedule
14
Table 3
Immunization schedule by medical indication
16
17
Notes
Routine vaccination
Persons NOT moderately or severely
immunocompromised
• Outlines vaccination series by age
group and COVID -19 vaccination
history.
Special situations
Persons who ARE
moderately or
severely
immunocompromised
•Outlines vaccination
series by age group
and COVID -19
vaccination history.
19
20
21
22
23
Vaxelis and PedvaxHIB preferred for
primary series in American Indian
and Alaska native infants.
Guidance for use of Hib in
children receiving early
component complement
inhibitor.
24
25
26
27
28
29
30
31
Appendix
Contraindications and precautions
33
For more information, contact CDC
1-800-CDC-INFO (232 -4636)
TTY: 1 -888-232-6348 www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official
position of the Centers for Disease Control and Prevention.Thank you!
Questions?